Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR), to no one’s surprise, remains volatile. Notably, the stock hit an intraday low of $17.60 on October 5th, and closed Thursday 19.5% … Continue Reading
Read NowLong Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced disappointing news earlier this year for its cancer compound perifosine, and the stock remains in the penalty box. However, the story … Continue Reading
Read NowLong Ideas - Trading in Amicus Therapeutics (NASDAQ:FOLD) picked up considerably in the last few days, driving the stock up 19% to a high of $6.15 on Tuesday … Continue Reading
Read NowLong Ideas - In an 8K released on Wednesday morning, Amarin Corp. (NASDAQ:AMRN) revealed that the FDA still has not made a decision regarding Vascepa’s New Chemical Entity … Continue Reading
Read NowLong Ideas - Notwithstanding the take-out chatter on Illumina (NASDAQ:ILMN), with the potential that Roche (OTC:RHHBY) may take another run at the company for $60 a share (read … Continue Reading
Read NowLong Ideas - With Biogen-Idec’s (NASDAQ:BIIB) new multiple sclerosis (MS) treatment, BG-12, approaching a decision by the FDA (PDUFA date December 28th), enthusiasm in the medical community is … Continue Reading
Read NowLong Ideas - Following news that Elan’s (NASDAQ:ELN) developmental Alzheimer’s treatment, bapineuzumab, failed a Phase III trial in August and was subsequently discontinued, PropThink advised a position in … Continue Reading
Read Now